Clinical Trial Update: Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety and effectiveness of TQB2618 Injection Combined Therapy in advanced esophageal squamous cell carcinoma has been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• TQB2618 Injection Combined Therapy (TQB2618)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Esophageal Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED